Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gerald Kevin Oluka
Observed names:
Gerald Kevin Oluka,
Gerald Oluka
Institutions:
London School of Hygiene & Tropical Medicine,
MRC/UVRI & LSHTM Uganda Research Unit,
Medical Research Council,
Uganda Virus Research Institute
Observed institutions:
London School of Hygiene & Tropical Medicine,
MRC/UVRI & LSHTM Uganda Research Unit,
Makerere University,
Medical Research Council,
Uganda Virus Research Institute
ORCID:
0009-0001-7818-9259
Observed ORCID:
0009-0001-7818-9259
OpenAlex ID:
A5080642902
Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda
2023
·
Gerald Kevin Oluka
, Patricia Namubiru
, et al.
·
Frontiers in Immunology
·
51
PDF
Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months
2023
·
Jennifer Serwanga
, Violet Ankunda
, et al.
·
Frontiers in Immunology
·
24
PDF
Resilience and residuals beyond containment — The hidden burden of Bundibugyo Ebola virus survivorship sixteen years on: A cross-sectional observational study
2025
·
Raymond Ernest Kaweesa
, Joseph Ssebwana Katende
, et al.
·
New Microbes and New Infections
·
13
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy
2023
·
Jennifer Serwanga
, Claire Baine
, et al.
·
Frontiers in Immunology
·
13
PDF
An Optimised Indirect ELISA Protocol for Detection and Quantification of Anti-viral Antibodies in Human Plasma or Serum: A Case Study Using SARS-CoV-2
2023
·
Claire Baine
, Jackson Sembera
, et al.
·
BIO-PROTOCOL
·
12
Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens
2023
·
Hellen Nantambi
, Jackson Sembera
, et al.
·
Frontiers in Immunology
·
11
PDF
Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort
2025
·
Gerald Kevin Oluka
, Jackson Sembera
, et al.
·
Vaccines
·
10
PDF
Sustained S-IgG and S-IgA antibodies to Moderna’s mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations
2024
·
Jennifer Serwanga
, Violet Ankunda
, et al.
·
Frontiers in Immunology
·
10
Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals
2025
·
Jonathan Kitonsa
, Jennifer Serwanga
, et al.
·
Vaccines
·
8
PDF
The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies
2024
·
Violet Ankunda
, Joseph Ssebwana Katende
, et al.
·
Frontiers in Immunology
·
7
PDF
Sustained spike-specific IgG antibodies following CoronaVac (Sinovac) vaccination in sub-Saharan Africa, but increased breakthrough infections in baseline spike-naive individuals
2023
·
Jackson Sembera
, Claire Baine
, et al.
·
Frontiers in Immunology
·
7
PDF
Knowledge, attitudes and practices towards glycemic control among persons with diabetes mellitus at two tertiary hospitals in Uganda
2024
·
Daphine Ninsiima
, Timothy Lwanga
, et al.
·
African Health Sciences
·
4
Spike protein is a key target for stronger and more persistent T-cell responses—a study of mild and asymptomatic SARS-CoV-2 infection
2023
·
Ivan Ssali
, Susan Mugaba
, et al.
·
International Journal of Infectious Diseases
·
4
PDF
Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles
2024
·
Jennifer Serwanga
, Gerald Kevin Oluka
, et al.
·
PLoS ONE
·
3
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort
2024
·
Jennifer Serwanga
, Laban Kato
, et al.
·
Frontiers in Immunology
·
3
Geographical Differences in SARS-CoV-2 Antibody Response Dynamics and Neutralisation Profiles to Mild COVID-19: Lessons from a UK–Uganda Comparison
2025
·
Laban Kato
, Jackson Sembera
, et al.
·
Vaccines
·
2
Neutralization and ADCC reveal divergent spike-subdomain targeting across SARS-CoV-2 vaccine platforms in an African cohort
2025
·
Gerald Kevin Oluka
, Joseph Ssebwana Katende
, et al.
·
iScience
·
1
PDF
Two Decades Later: Long-Term Multisystem Sequelae and Subclinical Organ Dysfunction in Sudan Ebola Virus (SUDV) Survivors
2025
·
Raymond Ernest Kaweesa
, Joseph Ssebwana Katende
, et al.
Two Decades Later: Long-Term Multisystem Sequelae and Subclinical Organ Dysfunction in Sudan Ebola Virus (SUDV) Survivors. Persistent Sequelae in Sudv Survivors after 25 Years
2025
·
Raymond Ernest Kaweesa
, Joseph Katende Ssebwana
, et al.
·
SSRN Electronic Journal
Silent Symptoms, Active Immunity: Insights into Early-Stage Cytokine Expressions in Ugandan Mild and Asymptomatic COVID-19 subjects
2023
·
Arthur Kalyebi Watelo
, Violet Ankunda
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
20
Citation count:
183
H-index:
8
I10-index:
8
Year
Topic
Type